• Researcher Profile

    George D. Demetri, MD

     
    Director, Center for Sarcoma and Bone Oncology
    Senior Vice President for Experimental Therapeutics
    Institute Physician


    Professor of Medicine, Harvard Medical School

    Center/Program

    Sarcoma

    Office phone: 617-632-6563
    Fax: 617-632-3408

    Preferred contact method: office phone

    View Physician Profile
     
     

    Research Department

    Medical Oncology/Solid Tumor Oncology

    Interests

    Soft tissue sarcoma, Bone sarcomas, Gastrointestinal stromal tumors (GIST), Developmental therapeutics

    Area of Research

    Molecular Targeted Agents and Signal Transduction Inhibitors

    Dana-Farber Cancer Institute
    450 Brookline Avenue
    Dana 1212
    Boston, MA 02215

    Biography

    Dr. Demetri is director of the Center for Sarcoma and Bone Oncology at DFCI, director of the Ludwig Center at Dana-Farber/Harvard Cancer Center, and executive director for Clinical and Translational Research at the Ludwig Institute for Cancer Research. 

    Recent Awards

    • Claire W. and Richard P. Morse Research Award, 2005
    • Emil J. Freireich Award in Clinical Cancer Research, 2002
    • Focused Giving Program Award, Johnson and Johnson Foundation, 1993

    Research

    Molecular Targeted Agents and Signal Transduction Inhibitors

    Sarcomas are a microcosm of solid tumor oncology: different sarcomas are increasingly being defined by molecular signatures and biological characteristics rather than by simple histopathology. Our group is translating this research on the basic biology of sarcomas into new therapeutics directed at novel targets.

    The foremost example of our team's work has been the development of tyrosine kinase inhibitors as effective therapies for patients with gastrointestinal stromal tumor (GIST). By targeting the specific molecular signals of GIST, we have validated the concept that a human solid tumor can be treated by signal transduction inhibitors. This work led to the development and FDA approval of imatinib mesylate (Gleevec) as an effective therapy for patients with metastatic or unresectable GIST, and underlies our ongoing research in other novel agents, such as the kinase inhibitor SU11248.

    Another example of molecular targeting of sarcomas in drug development is our pioneering interest in differentiation therapy for patients with liposarcomas. This research targets a nuclear receptor known as PPAR-gamma, which plays a role in the normal development of fat cells, and induces differentiation in liposarcomas to decrease proliferation. Larger studies based on our pilot data are now being designed to test the clinical value of this treatment, which we are refining with newer agents and methods.

    Our group also is developing other agents against sarcomas, such as the natural product known as ET-743, derived from a marine organism. This drug, which binds to the DNA minor groove, has shown important clinical activity against several subtypes of sarcomas both in the laboratory and in extensive clinical trials. We are optimizing the dosage for this agent and moving forward in collaboration with other cancer centers to test the worth of this new drug.

    Our multidisciplinary research team, including dedicated representatives from surgical oncology, radiation oncology, pathology, and other clinical arenas, works closely with laboratory investigators so that we can offer promising treatments of scientific merit to patients with sarcomas of soft tissue and bone.

    Investigators

    • George, Suzanne, MD
    • Morgan, Jeffrey A., MD
View Physician Directory

Find a Clinical Trial

Support Cancer
Research

Give Now